^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    TargetPrint®

    Company:
    Agendia
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    Target Print is a diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor (ER), progesterone receptor (PR) and Human Epidermal growth factor Receptor 2 (HER2) in breast cancer tumor biopsies. TargetPrint runs on Agendia’s new High Density Chip. Its results give a precise molecular read-out of prognostic parameters for breast cancer and provide physicians and patients with reliable guidance on the most suitable treatment for each individual patient.
    Cancer:
    Breast Cancer
    Gene:
    ER (Estrogen receptor), HER-2 (Human epidermal growth factor receptor 2)
    Method:
    Immunohistochemistry (IHC) / Fluorescence in situ hybridization (FISH)
    Confirmatory trial(s)
    MINDACT
    ,
    NCT00433589
    |
    Ann Oncol